Effective sequence screening depends not just on the science but on systems – people, processes and data working together. With a common standards framework, we move from bespoke checks to scalable, reliable defences against misuse of biotechnology.

Christina LaPosa is Program Manager within the Applied Biology group at RTX BBN Technologies, she supports interdisciplinary initiatives at the intersection of synthetic biology, data systems and biosecurity, bringing engineering-management experience to complex programs involving nucleic acid screening, automated workflows and threat-aware bioscience. According to her LinkedIn profile, Christina holds a degree from Virginia Tech and has built strong skills in coordinating multi-stakeholder projects in the Washington, D.C.–Baltimore region.

In her role, Christina helps translate cutting-edge synthetic biology risks into programmatic action – including supporting development of screening protocols, facilitating standards-oriented workshops, and ensuring that technical innovations align with operational and regulatory realities.